Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo.
Source explicitly identifies 2024-05-13 as the announcement or milestone date; pin uses this date. Investment period: New French biomanufacturing commitments announced May 2024.[1]
Sanofi announced more than €1 billion of additional bioproduction investment at Vitry-sur-Seine, Le Trait and Lyon Gerland. The new plan builds on €2.5 billion previously committed to major French projects.
Source explicitly identifies 2025-05-14 as the announcement or milestone date; pin uses this date. Investment period: Through 2030.[1]
Sanofi announced its intention to invest at least US$20 billion in the United States through 2030. The commitment includes increased R&D spending and billions of dollars for domestic manufacturing.
46-48 Avenue de la Grande Armée, Paris, FranceSanofi
CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins86% CONFIDENCEOverall confidence: 86%How well the pin's source and references back up its dates.Weighted average of how firmly 3 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better
Sanofi's[1] press release is dated February 10, 2026 and says it accepted tendered shares for payment and completed the merger that day, after the tender offer expired on 9 February.
On 10 February 2026 Sanofi completed the acquisition of vaccine maker Dynavax at US$15.50 a share in cash, adding the two-dose hepatitis B vaccine Heplisav-B and a shingles vaccine candidate.
46-48 Avenue de la Grande Armée, Paris, FranceSanofi
CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins87% CONFIDENCEOverall confidence: 87%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better
Sanofi's[1] press release is dated "Paris, February 12, 2026" and says the board met on 11 February; pharmaphorum[3] and Pharmaceutical Technology[4] both report it on 12 February.
On 12 February 2026 Sanofi's board said it would not renew Paul Hudson, whose last day as CEO was 17 February, and named Merck KGaA chief Belén Garijo to succeed him after the 29 April shareholder meeting.
46-48 Avenue de la Grande Armée, Paris, FranceSanofi
CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins86% CONFIDENCEOverall confidence: 86%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better
Sanofi's[1] press release is datelined "Paris, June 23, 2026" and PharmaTimes[4]' report of the approval is dated 23 June 2026.
On 23 June 2026 the European Commission approved Sanofi's Cenrifki (tolebrutinib) for secondary progressive multiple sclerosis without relapses, the first EU medicine aimed at disability progression in that group.
46-48 Avenue de la Grande Armée, Paris, FranceSanofi
CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins85% CONFIDENCEOverall confidence: 85%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better
Sanofi's[1] press release is datelined "Paris, July 24, 2026" and HCPLive[3] and BioSpace[4] carried it the same day.
On 24 July 2026 Sanofi announced it was discontinuing development of its OX40-ligand antibody amlitelimab in moderate-to-severe atopic dermatitis and would not file it with regulators.
46-48 Avenue de la Grande Armée, Paris, FranceSanofi
CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins87% CONFIDENCEOverall confidence: 87%How well the pin's source and references back up its dates.Weighted average of how firmly 3 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better
Sanofi's[1] results release is dated July 30, 2026, as is the Pharmaletter[3] report of the guidance upgrade.
On 30 July 2026 Sanofi reported second-quarter sales up 17.8% at constant rates to EUR 11.6 billion and business EPS of EUR 2.09, and raised its 2026 outlook to about 10% sales growth.
46-48 Avenue de la Grande Armée, Paris, FranceSanofi
CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins86% CONFIDENCEOverall confidence: 86%How well the pin's source and references back up its dates.Weighted average of how firmly 3 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better
Sanofi's[1] press release is datelined "Paris and Tarrytown, NY, October 1, 2026" and the same release was furnished to the SEC[3].
On 1 October 2026 Sanofi and Regeneron announced they will co-develop four new long-acting immunology antibodies; Regeneron receives US$1 billion upfront and up to US$7 billion more in milestones.
Blueprint Medicines, 45, Sidney Street, University Park, Cambridgeport, Cambridge, Middlesex County, Massachusetts, 02139, United StatesSanofi
SCHEDULEDDate confidence: SCHEDULEDGiven as scheduledHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all SCHEDULED pins82% CONFIDENCEOverall confidence: 82%How well the pin's source and references back up its dates.Weighted average of how firmly 3 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better
Given as scheduled, per the Massachusetts WARN tracker (mass.gov[2], week ending 18 Sept 2026): "Blueprint Medicines Corporation (aka Sanofi Company Blueprint) Cambridge, MA ... 10/9/2026 - 6/25/2027 229"; the Boston Globe via STAT: positions "will be cut between Oct. 9 and late June 2027".
A year after its $9.1 billion takeover, Sanofi is laying off 229 former Blueprint Medicines staff and closing Blueprint's two Sidney Street offices in Cambridge, with separations from 9 October 2026 to late June 2027.
ESTIMATEDDate confidence: ESTIMATEDA target, not a fixed dateHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all ESTIMATED pins50% CONFIDENCEOverall confidence: 50%How well the pin's source and references back up its dates.Weighted average of how firmly 1 reference, the source included, supports the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins from 50% to 74% confidence
ClinicalTrials.gov[1] lists 2027-06-07 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.
Sanofi's phase 3 trial of PCV21 Vaccine in pneumococcal immunization reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,195 participants. This is a phase 3 randomized, modified double-blind study whose purpose is to measure whether 3 lots of the investigational pneumococcal vaccine PCV21 can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) in a similar way (ie, same immune response) when they are given to infants aged from approximately 2 months (42 to 89 days) and are safe compared to a licensed 20-valent pneumococcal vaccine (20vPCV) (Prevnar 20™). The study duration per participant will be up to approximately 17 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 months of age.
ESTIMATEDDate confidence: ESTIMATEDA target, not a fixed dateHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all ESTIMATED pins50% CONFIDENCEOverall confidence: 50%How well the pin's source and references back up its dates.Weighted average of how firmly 1 reference, the source included, supports the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins from 50% to 74% confidence
ClinicalTrials.gov[1] lists 2028-03-13 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.
Sanofi's phase 3 trial of MenQuadfi in meningococcal infection reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,568 participants. The purpose of this study is to describe the safety and immunogenicity of MenACYW conjugate vaccine compared with locally-licensed meningococcal vaccines in healthy infants and toddlers in China. Study details include: * Study duration (including 6-month safety follow-up after the last dose): * Cohort I (Groups 1 and 2): approximately 211 or 271 days (approximately 7 or 9 months) * Cohort II (Groups 3 and 4): up to 18 months * Cohort III (Groups 5 and 6): up to 21 months * Cohort III (Group 7): approximately 16 months * Vaccination Visits Period: * Cohort I (Groups 1 and 2): a 2-dose vaccination at V01 (D01) and V02 (D31) or V03 (D91). Two blood samples are collected pre-vaccination (D01) and 30 days post the 2nd dose of vaccination (D61 or D121).
